NASDAQ · TWST

Twist Bioscience Corporation

Healthcare · Biotechnology

$166.99▲ 7.35% ($11.43)at close

After hours$167.90▲ 0.54%7:53 PM ET

52-week

$23.30$167.05

No multiple

What the market price implies · Reverse DCF

Historical revenue grew by 29.88%/yr over the past 4 years.

Selected forecast · Base scenario

15.6%/yr · actual 10-year annualized revenue growth

Year 1 growth: 24.51%

Market-implied · Base operating assumptions + edited margins

Unavailable · flat 10-year annualized revenue growth

Reverse DCF solves revenue growth itself using Base operating assumptions and your edited margins. Changing forecast growth alone does not change the implied rate. This is a model-implied requirement, not an analyst forecast.

No supported revenue growth rate matches this price with these operating assumptions.

Valuation

Recommended · Revenue & margin DCF

Price used

$166.99

Estimated value / share

Unavailable

Base scenario

USD · TTM ending 2026-06-30

Every projected year produces negative free cash flow, so the model returns a negative enterprise value. A discounted-cash-flow valuation cannot be defended on those inputs, so it is not shown.

Year 1 growth 24.51% · Ending margin 0% · Discount rate 17.2%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 18, 2026, 8:00 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 21, 2026, 1:46 AM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Optimism is getting priced inModerate confidence

1Y Price: 497.46%Revenue (TTM): 19.19%FCF (TTM): -35.52%P/S: 77th pct

What changed

The stock rose 497.46% over the last year. Revenue grew 19.19% over the trailing twelve months. Operating margin moved from -39.3% to -31.91%. Free cash flow declined 35.52% over the trailing twelve months.

What the market seems to be pricing

The stock is trading toward the richer end of its historical P/S range (77th percentile) while business metrics are improving. More of the upside is already embedded in the multiple now.

What would invalidate this read

Operating margin is at -31.91% — continued expansion would be needed to justify the premium. Revenue growth of 19.19% is encouraging, but any deceleration puts the stretched multiple at risk. This read changes if revenue, margins, and cash flow continue to improve faster than expected — in that case the richer multiple could still prove conservative.

Performance

Return analysis

Company profile

Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA.

CEOEmily Marine Leproust

SectorHealthcare

IndustryBiotechnology

Employees979

IPO dateOct 31, 2018

https://www.twistbioscience.com

Market multiples

Forward P/E—

EV/EBITDA-31.43

Enterprise value$1.64B

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth23.24%

Gross margin (FY2025)50.72%▲8.1ppvs FY2024

Operating margin (FY2025)-36.18%▲34.4ppvs FY2024

ROE-29.59%▼13.2ppvs FY2025

Analyst consensus

RatingBuy

Target price$116.33▼30.34%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 13, 2026

Q4 FY26 · EPS est -$0.44 · Revenue est $123.57M

View